Mansoor Raza Mirza, MD, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, discusses PARP and antio-angiogenic agents in platinum-sensitive disease and awaiting phase III trial results in order to move towards a chemotherapy-free era in gynecological cancer. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.